Arcus Biosciences, Inc. (RCUS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Arcus Biosciences, Inc. (RCUS) is up 2.7% since the beginning of the year. At $24 per share, RCUS is trading 14.8% below its 52-week high of $29. Investors who bought $1,000 worth of RCUS shares 5 years ago would now be looking at an investment worth $987.

Arcus Biosciences, Inc. (RCUS) has returned 2.69% so far this year and 143.97% over the past 12 months.

Based on dividend-adjusted daily data since Mar 15, 2018, RCUS's average daily return is +0.13%, while the average monthly return is +2.25%. At this rate, an investment would double in approximately 2.6 years.

Historically, 46% of months were positive and 54% were negative. The best month was Apr 2020 with a return of +90.3%, while the worst month was Dec 2022 at -41.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, RCUS closed higher 48% of trading days. The best single day was Apr 16, 2020 with a return of +89.4%, while the worst single day was Dec 20, 2022 at -32.5%.

Arcus Biosciences, Inc. has an annualized alpha of 13.45%, beta of 1.35, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since March 16, 2018.

• This stock participated in 95.85% of S&P 500 Index downside but only 65.65% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RCUS ranks 90 for risk / return — in the top 90% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Arcus Biosciences, Inc. (RCUS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Arcus Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arcus Biosciences, Inc. was 85.83%, occurring on Apr 4, 2025. The portfolio has not yet recovered.

The current Arcus Biosciences, Inc. drawdown is 49.52%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Arcus Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Arcus Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.